AUTHORS
Fuguo Liu, PhD, Xingyu Deng2, Wenxin Xu3, Veronica W Hui4, Andreia Maia, MS, PhD5, Jiting Tang6, Maily Nyugen7, Mubin Tarannum8, Shaobo Yang9, Shikha Gupta10, Stephanie Sendker, MD11, Alaa Kassim Ali, PhD12, Remy Dulery, MD, PhD13, Roman Shapiro, MD14, John Koreth, MD,MBBS,PhD,DPhil15, Andrew A. Lane, MD, PhD16, Daniel J DeAngelo, MD, PhD17, Mahasweta Gooptu, MD18, Jose A Cancelas, MD, PhD19, Jianzhu Chen20, Robert J Soiffer, MD21, Catherine J. Wu, MD22, Jerome Ritz, MD23, Toni K Choueiri24, Rizwan Romee, MD25
AFFILIATIONS
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
15 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
16 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
17 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
18 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
19 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
20 Koch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA, Cambridge, Massachusetts, United States
21 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
22 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
23 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
24 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
25 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
ABSTRACT
Background. Acute myeloid leukemia (AML) remains a difficult target for immunotherapy because few surface antigens are truly leukemia specific, and many candidates, including CD33, CD123, CLL-1, and FLT3, are also expressed on normal hematopoietic stem/progenitor cells, limiting the therapeutic window. AML also resides in an immunosuppressive bone marrow niche enriched in TGF-β, which impairs effector-cell function and supports leukemic survival. CD70 is an attractive alternative target because it is frequently expressed on AML blasts with limited expression on normal hematopoietic stem cells. We hypothesized that CD70 CAR-NK cells engineered to use local TGF-β as a tumor-selective trigger for cytokine delivery would enhance NK-cell activation, persistence, and antileukemic activity while limiting systemic toxicity.
Method. To identify the optimal proinflammatory payload for CD70 CAR-NK cells in AML, we generated CD70 CAR-NK cells individually armed with IL-12, IL-15, or IL-18. The CAR comprised the CD27 ectodomain, CD8 transmembrane domain, and 4-1BB/CD3ζ signaling domains, with each cytokine linked by a P2A sequence. IL-12 showed the greatest anti-AML activity and was selected for following studies. We engineered TGF-β sensor circuits using SMAD-responsive elements with minimal SV40 or MLP promoters to drive conditional IL-12 expression in response to tumor-derived TGF-β. IL-18 was subsequently incorporated into the CAR to further enhance anti-AML activity.
Primary NK cells were transduced and evaluated in vitro for activation, proliferation, cytokine secretion, and cytotoxicity against MOLM13, OCI-AML2, and OCI-AML3 cells. Cytotoxicity was measured by Annexin V/7-AAD staining, IL-12/IL-18/IFNγ secretion by ELISA, and proliferation by CellTrace Violet (CTV) dilution. In vivo therapeutic efficacy was assessed in NSG-Tg(Hu-IL15) mice bearing MOLM13-luciferase xenografts. Endpoints included tumor burden, NK-cell persistence, infiltration, activation, and safety assessment with body weight monitoring and day 7 assessment of cytokines including IL-12, IL-18, IL-1β, IL-2, IL-6, IFNγ, and GM-CSF.
Results. CD70CAR NK cells armed with IL-12, IL-15, or IL-18 showed greater cytotoxicity against AML cell lines than unarmed CD70CAR NK cells, with CD70CAR-IL-12 demonstrating the strongest activity. In vivo, CD70CAR-IL-12 produced the lowest tumor burden by bioluminescence imaging and the longest survival compared with CD70CAR-IL-15 (p=0.0477) and CD70CAR-IL-18 (p=0.0018), supporting IL-12 as the optimal payload. We next generated CD70CAR-IL12S, in which IL-12 expression is controlled by a TGF-β sensor. CD70CAR-IL12S showed robust CAR expression and strong TGF-β-inducible IL-12 secretion (20.3 vs 159.6 pg/mL; p=0.0004), but inducible IL-12 alone only partially reversed TGF-β-mediated suppression. We therefore developed CD70CAR-IL12S/18 NK cells, which retained robust CAR expression, TGF-β-inducible IL-12 production, and high constitutive IL-18 secretion (~2,000 pg/mL). Consistent with recombinant TGF-β stimulation, co-culture with LAP-TGF-β+ MOLM13 cells significantly increased IL-12 secretion (15.5 vs 80.4 pg/mL; p=0.0018). Functionally, TGF-β pretreatment reduced the cytotoxicity of CD70CAR, CD70CAR-IL-12, and CD70CAR-IL-18 NK cells against MOLM13, OCI-AML2, and OCI-AML3 cells. In contrast, TGF-β-pretreated CD70CAR-IL12S/18 NK cells maintained cytotoxicity and IFNγ production at levels comparable to untreated controls, indicating resistance to TGF-β-mediated suppression. Proliferation assays (CTV dilution) also showed increased late-generation daughter cells after 6 days with MOLM13 targets, consistent with enhanced proliferation. In vivo the use of CD70CAR-IL12S/18 was safe and associated with robust tumor control without significant increase in the levels of CRS associated cytokines.
Conclusion. Here we report a first-in-class TGF-β sensor cytokine circuit that enables marrow-selective delivery of biologic payloads, including highly activating IL-12. We identify IL-12 as the most effective cytokine payload for CD70CAR NK cells in AML and show that pairing TGF-β-inducible IL-12 with constitutive IL-18 overcomes TGF-β-mediated suppression while preserving cytotoxicity, IFNγ production, and proliferation. This approach uses the immunosuppressive AML bone marrow niche to trigger local cytokine delivery and drive strong anti-leukemia responses, supporting further evaluation in an early-phase trial in patients with advanced AML.
DISCLOSURES
Fuguo Liu, PhD: No relevant conflicts of interest to declare.